Dec-10-12 By IdeaConnection
An article posted on the Genetic Engineering and Biotechnological News website provides commentary on the pharma industry’s engagement with open innovation.
It features an intriguing observation of Patrick Vallance, president, pharmaceuticals R&D at GlaxoSmithKline. He notes that when R&D costs were spiraling the drug pipeline was small. But today, as budgets are shrinking the pipeline is growing. Vallance attributes the increase in productivity to pharma companies becoming more outward-facing.